The role of moclobemide in endogenous depression: a survey of recent data.
Earlier studies demonstrated that moclobemide has good efficacy as an antidepressant. Its efficacy was comparable to reference antidepressants, both in endogenous and non-endogenous depression. A meta-analysis was performed of recent data from more than 2000 patients who had participated in double-blind trials with moclobemide and comparison drugs. Based on HAMD-17 baseline scores, the sample was divided into three groups according to the severity of depression. In all three, moclobemide was as effective as comparison drugs, both in endogenous and non-endogenous depression. The antidepressant efficacy of both moclobemide and reference drugs was more pronounced in endogenous than in non-endogenous depression, whatever the severity.
Woggon
B
B
Psychiatrische Universitätsklinik Zürich, Switzerland.
D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D015201:Meta-Analysis as Topic; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide